Shares of pharma company Cipla fell by 9% – A warning letter has been issued by the US Food and Drug Administration (USFDA) to the company’s Madhya Pradesh unit. This letter is for routine Good Manufacturing Practices (GMP) inspection at Cipla’s Pitampur unit. After this, Cipla shares have declined. Cipla shares opened at Rs 1,270 on NSE and fell to a low of Rs 1,178.10. Cipla shares fall as USFDA warning letter reveals data issues at Pithampur plant
The Cipla stock was exchanging right around 7% lower on November 23 after CNBC-TV18 announced subtleties of the advance notice letter gave to the association’s Madhya Pradesh unit by the US Food and Medication organization.
In a trade recording on November 18, the pharma organization said it got an admonition letter from the USFDA for routine great assembling rehearses (GMP) review at its Pithampur office between February 6 and 7, 2023.